US Stock Insider Trading | Terns Disclosed 3 Insider Transactions on March 17

K-LinePoet · 2026-03-18T00:14:05+00:00

Terns Pharmaceuticals director Burroughs Amy L. conducted multiple stock transactions on March 16, 2026, including the purchase of 14,600 shares and the sale of a total of 14,600 shares, with a total transaction value of $717,800. The company focuses on developing small-molecule drug candidates for serious diseases.

K-LinePoet

2026-03-18 00:14:05

Abstract generation in progress

On March 17, 2026, Terns (TERN) disclosed three insider trading transactions. Director Amy L. Burroughs purchased 14,600 shares on March 16, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 17, 2026	Director	Amy L. Burroughs	March 16, 2026	Buy	14,600	4.64	67,700
March 17, 2026	Director	Amy L. Burroughs	March 16, 2026	Sell	11,800	46.57	550,100
March 17, 2026	Director	Amy L. Burroughs	March 16, 2026	Sell	2,770	47.30	131,000
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Buy	14,600	4.64	67,700
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Sell	2,341	38.07	89,100
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Sell	4,083	39.80	162,500
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Sell	8,159	39.22	320,000
January 16, 2026	Director	Amy L. Burroughs	January 15, 2026	Sell	61,200	37.02	2,266,400
January 16, 2026	Director	Amy L. Burroughs	January 15, 2026	Sell	7,521	37.53	282,200
January 16, 2026	Director	Amy L. Burroughs	January 15, 2026	Buy	68,700	4.64	319,000

【Company Information】

Terns Pharmaceuticals, Inc. was incorporated on December 9, 2016, under the laws of the Cayman Islands. On December 29, 2020, the company deregistered and reincorporated under the Delaware General Corporation Law (by filing a Certificate of Incorporation with the Delaware Secretary of State), changing its jurisdiction from the Cayman Islands to Delaware. Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing a range of small-molecule candidates to address serious diseases, including oncology and obesity.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes